Clinical trials located in

Elbląg

Elbląg city is located in Poland. Currently, 11 clinical trials are being conducted in this city.

Elbląg, a city in northern Poland, boasts a rich history dating back to 1237. Known for its Old Town, meticulously reconstructed after WWII, it mirrors the original medieval layout. The city is a gateway to the Elbląg Canal, an engineering marvel from the 19th century, featuring a unique system of slipways to navigate boats over land. Elbląg also played a pivotal role in the Teutonic Order, with remnants of its past visible in the architecture and cityscape. Its cultural tapestry is enriched by the Elbląg Brewery, one of Poland’s oldest.

  • CT-EU-00117206

    Study on Secukinumab for Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no active ingredients.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week for the first month, and then once a month after that for another couple of months. The doctors will be keepin’ a close eye on your shoulder symptoms like pain, weakness, stiffness, and any mechanical issues you might be havin’.

    The main thing they’ll be lookin’ at is how much your physical shoulder symptoms improve after 16 weeks of treatment with secukinumab compared to the placebo. They’ll be usin’ a special questionnaire called the Western Ontario Rotator Cuff Index to measure them symptoms.

    Now, durin’ the trial, you’ll need to keep takin’ any anti-inflammatory medicines you’re already on, and keep up with your physical therapy exercises too. But you won’t be allowed to get no steroid injections or increase your medicine doses without the doctors’ say-so.

    After the 16 weeks of treatment, there’ll be another 8 weeks where the doctors will check if the effects of the medicine are lastin’. So in total, you’d be in the study for around 6 months if you join up.

    DenmarkGreeceHungaryItalyPolandSpain
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    HungaryPolandRomaniaSpainUnited Kingdom
  • Study on ruxolitinib cream for hand eczema

    This study investigates the use of ruxolitinib cream for adults with chronic hand eczema, a skin condition causing itchy, red, and cracked skin on the hands. The cream is applied directly to the affected areas twice daily for 16 weeks. Participants in the study, who are adults with moderate to severe hand eczema, are either given ruxolitinib cream or a placebo cream. After 16 weeks, all participants can choose to continue with ruxolitinib cream for another 16 weeks. The study aims to find out if this cream can effectively reduce the symptoms of hand eczema, like itchiness and skin pain, and improve overall skin condition and quality of life. Around 180 people are taking part in this study, which doesn’t include healthy volunteers​.

    GermanyPoland
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Long-term study on Mirikizumab for active ulcerative colitis

    The study aims to evaluate the effectiveness and safety of the drug mirikizumab in individuals with a severe form of Ulcerative Colitis (UC). This comprehensive study involves many patients across various medical centers. Health improvement will be assessed using a specialized scoring method (MMS). The study will also closely monitor for any adverse effects.

    AustriaBelgiumCzechiaDenmarkGermanyHungaryItalyPolandRomaniaUnited Kingdom
  • Testing efavaleukin alfa’s effect on moderately to severely active ulcerative colitis

    This trial is about a drug named efavaleukin alfa, which might be helpful for people suffering from ulcerative colitis. Participants will either receive one of three doses of this drug or placebo for 12 weeks. If the treatment works, participants can choose to continue it for up to 52 weeks. If initially received placebo didn’t work, treatment will be switched to efavaleukin alfa.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpain
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    AustriaBelgiumCzechiaDenmarkFinlandGermanyHungaryItalyPolandPortugalSlovakiaSpainSweden
  • Testing the safety and effectiveness of a new drug in adults with atopic dermatitis

    This trial involves the exploration of a new medication, GSK1070806, for adults afflicted with moderate to severe atopic dermatitis, a skin condition characterized by redness and itching. Over a 16-week period, participants are administered either the new medication or a placebo, a substance devoid of therapeutic properties. This double-blind study ensures that neither the participant nor the doctor is aware of the treatment allocation. Parameters assessed include the medication’s efficacy, safety, drug metabolism within the body, and its impact on the disease. An essential metric is the EASI score, reflecting the severity of the skin condition. Additional assessments encompass the evaluation of itchiness levels, pain intensity, and the disease’s effect on sleep and fatigue. Physicians also document any adverse events, which pertain to unexpected medical incidents related to the drug, and ascertain causality.

    BulgariaCzechiaFranceGermanyGreeceItalyPolandSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Poland:

.